The recent article by An et al. [1] provided for highly stimulating reading. Interestingly, recent data suggests that troglitazone may attenuate tumor growth in a number of systemic malignancies besides accentuating the radio-sensitivity of cervical carcinomas.
For instance, troglitazone attenuates tumor growth in gastric malignancies. It mediates this role by modulating the early growth response protein 1 (EGR-1) pathway. It accentuates nonsteroidal anti-inflammatory drug-activated gene 1 (NAG-1) expression within the cancerous cells [2] . As a result it augments intra-tumoral apoptosis within the gastric carcinomas. These effects are time dependent. Similar effects have been seen in colon carcinomas; it mediates this role by accentuating nuclear factor kappa B (NFκB) inactivation via attenuation of glycogen synthase kinase (GSK)-3β activity within the tumor cells. Intra-tumoral Bax levels are accentuated. As a result apoptosis is markedly augmented [3] . Cyclin B1 and cyclin D1 levels are attenuated. G0/G1 phase arrest is typically seen. Caspase-9 levels are typically accentuated. Troglitazone also decreases FLIP activity and thereby increase the sensitivity of the colon cancer cells to TRAIL induced apoptosis [4] . The anti-neoplastic activity of troglitazone is augmented by loss of X-linked inhibitor of apoptosis protein (XIAP) [5] .
Similarly, troglitazone decreases tumor growth in breast cancers. It mediates this role by attenuating human telomerase reverse transcriptase (hTERT) expression within the mammary malignancies [6] . Telomerase activity is markedly reduced. Cdk2 and Cdk4 levels are markedly attenuated. As a result, increased G1 phase arrest is typically seen. In addition, it inhibits histone deacetylase resulting in attenuated phosphatidylinositol 3-kinase (PI3K) signaling [7] . p27 levels are accentuated [8] . These effects are dose dependent.
Similar effects are seen in prostate malignancies. Troglitazone primarily exerts these anti-neoplastic effects by accentuating intra-tumoral inactivation of NFκB. It mediates this role by suppression of GSK-3β expression [9] . Troglitazone also mediates this role by augmenting Erk phosphorylation within the cancerous cells. It also modulates p21 and c-myc expression [10] . It down-regulates expression of c-myc. As a result there is increased G0/G1 phase arrest [11] . These effects have been seen both in vivo and in vitro.
The above examples clearly illustrate the significant antineoplastic activity of troglitazone and the need for further studies in this regard.
